Forward Citations = 3

Loading Chart...

2 inventors (with patents filed for the assignee):

Chai Ezerzer (5 out of 6 patents)

Nicholas Harris (3 out of 7 patents)

5 patents: Sort by Forward Citations

1. 11926677 - Peptides and uses thereof for treating cancer (2024-03-12),

2. 11078255 - Ca2+ regulated binding agents (2021-08-03),

3. 9931376 - Cytokine receptor peptides, compositions thereof and methods thereof (2018-04-03),

4. 9416158 - Cytokine receptor peptides, compositions thereof and methods thereof (2016-08-16),

5. 8703911 - Cytokine receptor peptides, compositions thereof and methods thereof (2014-04-22),

Company Overview

Symthera Canada Ltd. is a leading biopharmaceutical company focused on developing innovative therapies for rare and orphan diseases. With a strong commitment to improving patients' quality of life, Symthera is dedicated to advancing research and delivering cutting-edge treatments to those in need. Through collaboration with healthcare professionals, patients, and advocacy groups, Symthera strives to make a meaningful impact on the lives of individuals affected by these challenging conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

5 Patents

#283 in Toronto

#2,851 in Canada

Toronto, Canada

Symthera Canada Ltd.

Forward Citations = 3

2 inventors:

Chai Ezerzer (5 out of 6 patents)

Nicholas Harris (3 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Symthera Canada Ltd.. Retrieved from https://idiyas.com/company/symthera-canada

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]